Raising $1.2M in equity SeqOnce Biosciences, Inc.’s Reg CF offering is available from Republic. Please see our company presentation and visit Republic if interested in
New Research Facility to Advance Genomics SeqOnce Biosciences, Inc., a genomics company creating new tools to detect and analyze human disease, is thrilled to announce
Next Generation Sequencing (NGS) library construction is a workflow bottleneck. The processes of library construction for DNA and RNA sequencing are complex, error prone, costly, and in general are
Next-generation sequencing is, by definition, “massively parallel.” While the first 454/Curagen GS20 systems yielded a million reads per run, the latest sequencing platforms from Illumina,
SeqOnce is a company founded upon the idea that steps involved in Next Generation Sequencing (NGS) need to be both streamlined and simplified. Having developed
Current next Generation Sequencing (NGS) library construction is a bottleneck in the sequencing workflow. The processes of library construction for DNA and RNA sequencing are
